Precigen Inc (PGEN)

Precigen Inc (PGEN) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $2.3B; returns 1 day -3.1%, 1 week -3.1%, 1 year +45.6%.

Precigen Inc. (PGEN) is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative precision medicines for difficult-to-treat diseases. The company's primary revenue driver as of early 2026 is PAPZIMEOS (zopapogene imadenovec-drba), its first FDA-approved gene therapy, specifically for adult recurrent respiratory papillomatosis (RRP).

Groups PGEN belongs to

• Biotechnology
• Biopharmaceutical
• Gene Therapy
• Commercial Stage
• Commercial Stage Biotech
• Healthcare
• Oncology
• Precision Medicine
• Immunotherapy
• Life Sciences

PGEN financial model: income statement, cash flow and balance sheet